Ocuphire Pharma Investor Updates

P LO 5 Product Profile: Nyxol + Low-Dose Pilocarpine (LDP) Combo Moderate Use of Iris Dilator And Iris Sphincter Muscles To Improve Near Vision 0.75% Nyxol F O 0.4% 0.4% LDP Source: Ocuphire Clinical Trials (completed) Iris Dilator Muscle Inhibition Iris Sphincter Muscle Activation ● ● ● ● ● Active ingredient approved decades ago 505(b)(2) Novel MOA on iris dilator with 24+ hour durability with moderate 1+mm pupil reduction Chronic daily dosing of Nyxol at bedtime demonstrated no daytime redness Well-tolerated with no systemic effects Stable, preservative-free, single use vial Ⓡ Pilocarpine Opal Solution, US 0.4% • Active ingredient approved decades ago 505(b)(2) Known MOA on sphincter muscle with more potent miotic effects at approved doses (1%, 2%, 4%) Chronic daily dosing in daytime Low concentration avoids known tolerability issues: headache and browache ➤ redness Nyxol + LDP accommodative spasm causing loss of distance vision especially at night Ocuphire PHARMA

View entire presentation